Skip to content

Clinical Trials in Alzheimer’s Disease (CTAD) conference

Presentations related to Lecanemab back-up were given at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference, held December 4-7 in San Diego, USA.

BioArctic’s partner Eisai presented data from the ongoing Lecanemab back-up Phase 2b open label extension study in early Alzheimer’s disease as well as the study design and current status of the ongoing Phase 3 study, Clarity AD.

Professor Lars Lannfelt, Uppsala University and BioArctic, presented binding profiles of Lecanemab back-up and aducanumab to different forms of amyloid-beta.